Mosunetuzumab

CHEMBL4297788 Phase 4 Đã phê duyệt Antibody
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This bispecific antibody simultaneously binds to CD20 on B-cell lymphoma cells and CD3 on T cells, forcing the immune system's killer T cells into direct contact with cancer cells to destroy them. It offers a fixed-duration treatment option for patients with relapsed or refractory follicular lymphoma.

Lĩnh vực điều trị

Cơ chế tác dụng

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This bispecific antibody simultaneously binds to CD20 on B-cell lymphoma cells and CD3 on T cells, forcing the immune system's killer T cells into direct contact with cancer cells to destroy them. It offers a fixed-duration treatment option for patients with relapsed or refractory follicular lymphoma.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Mosunetuzumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297788. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.